{"id":"cd33","name":"CD33","symbol":"CD33","route":"/targets/cd33/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1659","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105383","uniprot":"https://www.uniprot.org/uniprotkb/P20138/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P20138","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1842","open-targets":"https://platform.opentargets.org/target/ENSG00000105383","civic":"https://civicdb.org/genes/945/summary","oncokb":"https://www.oncokb.org/gene/CD33","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD33","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD33","depmap":"https://depmap.org/portal/gene/CD33?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000105383-CD33","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/945","omim":"https://www.omim.org/entry/159590"}],"products":[{"id":"gemtuzumab-ozogamicin","name":"Gemtuzumab ozogamicin","status":"approved","modality":"ADC","route":"/drugs/gemtuzumab-ozogamicin/"}],"trials":[{"id":"aaml0531","name":"COG AAML0531","nct":"NCT00372593","phase":"3","status":"positive"},{"id":"alfa-0701","name":"ALFA-0701","nct":"NCT00927498","phase":"3","status":"positive"},{"id":"nct04293562","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","nct":"NCT04293562","phase":"3","status":"recruiting"}],"pathways":[],"companies":["actinium-pharmaceuticals","orum-therapeutics","pfizer","vor-biopharma"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}